Could a common diabetes drug shield your brain from stroke and dementia?
NCT ID NCT05356104
First seen Mar 07, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study tests whether a GLP-1 drug, similar to diabetes medications like Ozempic, can prevent the progression of cerebral small vessel disease—a condition that damages tiny blood vessels in the brain and leads to stroke, dementia, and mobility issues. Researchers will enroll 110 Chinese adults aged 55-80 with moderate-to-severe disease to see if the drug improves brain scans and thinking skills. The goal is to find a new way to protect the brain beyond just managing blood pressure and cholesterol.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL SMALL VESSEL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese University of Hong Kong
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.